- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Toxoplasmosis, congenital |
|---|
|
| Toxoplasmosis, postnatal |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Neutropenia [Lipka 2011], hyperphenylalaninaemia [SmPC].
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Pyrimethamine should be used with caution in kidney diseases [SmPC].
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Aminoquinolines | ||
|---|---|---|
| P01BA01 | ||
| P01BA02 | ||
| Biguanides | ||
|---|---|---|
| P01BB01 | ||
| Methanolquinolines | ||
|---|---|---|
| P01BC02 | ||
| P01BC01 | ||
| Artemisinin and derivatives, plain | ||
|---|---|---|
| P01BE03 | ||
| Artemisinin and derivatives, combinations | ||
|---|---|---|
| P01BF01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Hartwig NC, et al, Vademecum pediatrische antimicrobiële therapie, 2005
- Bausch Health Ireland Limited , SmPC Daraprim (RVG 00254) 31-08-2020, www.geneesmiddeleninformatiebank.nl
- Lipka B et al., Monitoring of plasma concentration of pyrimethamine (PYR) in infants with congenital Toxoplasma gondii infection--own observations., Wiad Parazytol., 2011, 57(2), 87-92
- GlaxoSmithKline GmbH & Co. KG, SmPC Daraprim (6101907.00.00), 07/2020
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
